Johns Hopkins researchers have found
that vitamin D may help fight multiple sclerosis, based on new studies
involving mice with a rodent form of the disease.
In new research published in the Proceedings of the National Academy of
Sciences, the so-called "sunshine vitamin" appeared to block
damage-causing immune cells from migrating to the central nervous system,
offering a potential explanation for why it may prevent or ease symptoms of the
neurodegenerative disease.
Researchers said the study was
prompted by observations that MS is more prevalent in regions of the world
where there is less sunshine, the main natural source of vitamin D.
"With this research, we learned
vitamin D might be working not by altering the function of damaging immune
cells but by preventing their journey into the brain," said lead
researcher Anne R. Gocke, an assistant professor of neurology at the Johns
Hopkins University School of Medicine. "If we are right, and we can
exploit Mother Nature's natural protective mechanism, an approach like this
could be as effective as and safer than existing drugs that treat MS."
MS causes the immune system to
wrongly attack a person's own cells — specifically the fatty protein called
myelin that insulates nerves and helps them send electrical signals that
control movement, speech, and other functions. The immune system primes
so-called T cells in the body's lymph nodes, preparing them to destroy myelin,
a process that can lead to blurred vision, weakness, and numbness.
For the new study, Gocke and her
colleagues gave mice the rodent form of MS and a high dose of vitamin D. The
results showed the vitamin protected the mice from showing symptoms of the
disease.
"Vitamin D doesn't seem to
cause global immunosuppression," Gocke explained. "What's interesting
is that the T cells are primed, but they are being kept away from the places in
the body where they can do the most damage."
About 400,000 Americans are living
with multiple sclerosis. Current popular immune-suppressing medications for MS,
such as natalizumab (Tysabri) and fingolimod (Gilenya), can take six to 12
weeks to be cleared from the body.
No comments:
Post a Comment